LABORATORIOS LIOMONT, S.A. DE C.V. – Trademark Portfolio

Entity Type: 03

LABORATORIOS LIOMONT, S.A. DE C.V. holds 24 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 24 filings in this category. Currently, 6 trademarks are registered. Notable registered marks include ANALGEN, LIOMONT, CICLOFERON, and CONAZOL CREAM. The owner is based in 05000 Mexico, D.F..

Adolfo Lopez Mateos No. 68

Delegacion Cuajimalpa

05000 Mexico, D.F. , MX

24 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

Trademark Classifications

LABORATORIOS LIOMONT, S.A. DE C.V.'s trademark portfolio spans 1 Nice Classification class, reflecting the scope of goods and services protected under their brand portfolio.

5
Pharmaceuticals (24 filings)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

Frequently Asked Questions

How many trademarks does LABORATORIOS LIOMONT, S.A. DE C.V. have?

LABORATORIOS LIOMONT, S.A. DE C.V. has 24 U.S. trademarks filed with the USPTO. Of these, 6 registered, 8 abandoned, 10 cancelled.

What trademark classes does LABORATORIOS LIOMONT, S.A. DE C.V. file in?

LABORATORIOS LIOMONT, S.A. DE C.V. files trademarks across 1 Nice Classification class. The most active classes are Class 5 (Pharmaceuticals). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.

What are LABORATORIOS LIOMONT, S.A. DE C.V.'s most well-known trademarks?

LABORATORIOS LIOMONT, S.A. DE C.V.'s registered trademark portfolio includes well-known marks such as ANALGEN, LIOMONT, CICLOFERON, and CONAZOL CREAM. These are among 6 currently registered trademarks in the portfolio.

What is LABORATORIOS LIOMONT, S.A. DE C.V.'s trademark registration success rate?

LABORATORIOS LIOMONT, S.A. DE C.V. has a 25% trademark registration rate, with 6 out of 24 resolved applications resulting in successful registration. Currently, 0 applications are pending review.